Medicare Premium Hike Will Help Build ‘Contingency Fund’ For Alzheimer’s Drugs
Executive Summary
But CMS cautions that the announcement should not be read as a preview of its upcoming national Medicare coverage decision on Aduhelm and similar treatments.
You may also be interested in...
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
CMS Expects 'Consistent' Coverage Of Amyloid PET Scans Even Without National Standard
Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.
Medicare Coverage Of Amyloid PET Scans In Alzheimer’s Expected To Be ‘Consistent,’ Even Without National Standard, CMS Says
Medicare has finally rescinded its 10-year-old national restrictions on covering the diagnostic now that advances in amyloid plaque-removing drugs have underscored the importance of PET scans.